A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Study identifier:D9090C00001

ClinicalTrials.gov identifier:NCT04994106

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5462, Placebo

Sex

All

Actual Enrollment

98

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 27 Jul 2021
Primary Completion Date: 20 Sept 2022
Study Completion Date: 20 Sept 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria